Predictive segnifacance of topoisomerase 2 alpha in patients with triple negative breast cancer

Abstract

More than 2 million new cases of breast cancer (BC) are registered annually. BC is the most common malignant disease among women, both in Ukraine and in the world. Triple-negative (TN) BC is a group of carcinomas where the expression of estrogen receptors (ER), progesterone receptors (PR), and overexpression of the HER2 receptor is absent making it the most problematic subtype of BC. Among all cases of BC, TNBC occurs in about 15% of cases and has a number of characteristic features: frequent occurrence in young women, rapid growth, and weak correlation between the size of the primary tumor and survival. The combination of clinical, pathomorphological, and molecular data allows us to predict the course of the disease and optimize treatment tactics. In TNBC, traditional targets (ER, PR, and HER2 receptors) for the treatment are missing, so the research of prognostically valuable markers remains promising, which allows for optimization treatment in such cases.